Advanced Research Center, Inc.

Az itteni vizsgálatok

Miről szól a helyszín 43 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Alzheimer-kór12 vizsgálat
• Skizofrénia9 vizsgálat
• Bipoláris zavar7 vizsgálat
• Depresszió6 vizsgálat
• Mild cognitive impairment4 vizsgálat
• Autizmus spektrumzavar3 vizsgálat
• Irritable bowel syndrome2 vizsgálat
• Migrén2 vizsgálat
• Crohn-betegség1 vizsgálat
• Dermatomyositis and polymyositis (myositis)1 vizsgálat
• Gout1 vizsgálat
• Insomnia1 vizsgálat

Fázis

• 3. fázis27 vizsgálat
• 2. fázis8 vizsgálat
• 2/3. fázis4 vizsgálat
• 1. fázis1 vizsgálat
• 4. fázis1 vizsgálat

Állapot

• Lezárult17 vizsgálat
• Toboroz14 vizsgálat
• Leállították7 vizsgálat
• Fut, nem toboroz2 vizsgálat
• Meghívásos bevonás2 vizsgálat
• Visszavonták1 vizsgálat

Fő szponzor

• Intra-Cellular Therapies, Inc.5 vizsgálat
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company5 vizsgálat
• Biohaven Therapeutics Ltd.4 vizsgálat
• Janssen Research & Development, LLC4 vizsgálat
• Bristol-Myers Squibb3 vizsgálat
• és még 16

Futó vizsgálatok

• Toboroz

  A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

  NCT07424404· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás

  Contact: Steven Macina, Site 0077

• Toboroz

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

  NCT07288567· 3. fázis· Bristol-Myers Squibb· Forrás

  Contact: Steven Macina, Site 0077

• Toboroz

  A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

  NCT07280156· 2. fázis· Protalix· Forrás

  Contact: Head of Clinical Development

• Toboroz

  A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· 3. fázis· Bristol-Myers Squibb· Forrás

  Contact: Steven Macina, Site 0027

• Toboroz

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

  NCT06951698· 3. fázis· Bristol-Myers Squibb· Forrás

  Contact: Steven Macina, Site 0005

• Toboroz

  Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

  NCT06690398· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás

• Toboroz

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

  NCT06651567· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás

• Toboroz

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás

  Contact: Steven Macina, Site 1104

• Toboroz

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

  NCT06540833· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás

• Toboroz

  Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

  NCT06372964· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás

• Meghívásos bevonás

  Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

  NCT06245031· Cognito Therapeutics, Inc.· Forrás

• Toboroz

  Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  NCT06229210· 3. fázis· Intra-Cellular Therapies, Inc.· Forrás

• Toboroz

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás

  Contact: Steven Macina, Site 1104

• Meghívásos bevonás

  Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

  NCT05905926· 3. fázis· Ardelyx· Forrás

• Fut, nem toboroz

  Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

  NCT05397639· 3. fázis· Suven Life Sciences Limited· Forrás

• Toboroz

  Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

  NCT04743141· 3. fázis· Pfizer· Forrás

• Toboroz

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· 3. fázis· Pfizer· Forrás

• Fut, nem toboroz

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· 2/3. fázis· Janssen Research & Development, LLC· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Alzheimer-kór5 toboroz
• Skizofrénia5 toboroz
• Bipoláris zavar4 toboroz
• Autizmus spektrumzavar3 toboroz
• Migrén2 toboroz
• Gout1 toboroz
• Irritable bowel syndrome1 toboroz
• Mild cognitive impairment1 toboroz

Lezárt vizsgálatok

• Lezárult

  Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

  NCT06836063· 2. fázis· Suven Life Sciences Limited· Forrás

• Leállították

  Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

  NCT06431256· 3. fázis· Ironshore Pharmaceuticals and Development, Inc· Forrás

• Lezárult

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· 2. fázis· Biohaven Therapeutics Ltd.· Forrás

• Leállították

  BHV-7000 Open-Label Extension Bipolar Mania Study

  NCT06423794· 2. fázis· Biohaven Therapeutics Ltd.· Forrás

• Lezárult

  BHV-7000 Acute Treatment of Bipolar Mania

  NCT06419582· 2/3. fázis· Biohaven Therapeutics Ltd.· Forrás

• Lezárult

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· 2. fázis· Biohaven Therapeutics Ltd.· Forrás

• Leállították

  Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD

  NCT06215144· 2/3. fázis· Neurocentria, Inc.· Forrás

• Lezárult

  A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

  NCT05669014· 2. fázis· Amgen· Forrás

• Toboroz

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· 2/3. fázis· ACADIA Pharmaceuticals Inc.· Forrás

  Contact: Christine Murphy

• Lezárult

  A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

  NCT05628103· 3. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás

• Lezárult

  A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

  NCT05637801· Cognito Therapeutics, Inc.· Forrás

• Lezárult

  Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

  NCT05643534· 3. fázis· Ardelyx· Forrás

• Leállították

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· 3. fázis· Cassava Sciences, Inc.· Forrás

• Lezárult

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· 3. fázis· Janssen Research & Development, LLC· Forrás

• Leállították

  A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

  NCT05227209· 3. fázis· Sumitomo Pharma America, Inc.· Forrás

• Lezárult

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás

• Lezárult

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· 3. fázis· Cassava Sciences, Inc.· Forrás

• Leállították

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

  NCT04951609· 1. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· 3. fázis· Boehringer Ingelheim· Forrás

• Lezárult

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás

• Lezárult

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· 3. fázis· Novo Nordisk A/S· Forrás

• Lezárult

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· 3. fázis· Novo Nordisk A/S· Forrás

• Leállították

  Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

  NCT04708834· 3. fázis· Biohaven Pharmaceuticals, Inc.· Forrás

• Lezárult

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

  NCT04533529· 3. fázis· Janssen Research & Development, LLC· Forrás

• Lezárult

  A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

  NCT04085172· 4. fázis· Shire· Forrás